Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia

Sarcoidosis is a systemic disorder of unknown aetiology characterised by the formation of non-caseating epithelioid granulomas in involved organs. Although a spontaneous remission is frequent, up to 28–53% of patients may follow a persistent active course for more than 5 years [1, 2]. Outcome may be severe in a subset of these patients. Sarcoidosis treatment relies on three lines of therapies respectively corticosteroids, immunosuppressive medications and anti-TNFα therapy according to severity. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. ROTENBERG has nothing to disclose. Conflict of interest: Dr. Besnard has nothing to disclose. Conflict of interest: Dr. Brillet has nothing to disclose. Conflict of interest: Dr. GIRAUDIER reports and Grants from Novartis. Conflict of interest: Dr. Nunes reports grants and personal fees from Roche/Genentech, grants and personal fees from Boehringer Ingelheim, other from Sanofi, other from Gilead, outside the submitted work. Conflict of interest: Dr. VALEYRE reports personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Astra Zenecca, personal fees from Boehringer Ingelheim & Roche, outside the submitted work.